Daptomycin plus fosfomycin versus daptomycin monotherapy in treating MRSA: Protocol of a multicentre, randomised, phase III trial

BMJ Open

Volumn 5, Issue 3, 2015, Pages

  Shaw, Evelyn ^a   Miro J M ^a   Puig Asensio, M ^b   Pigrau, C ^b   Barcenilla, F ^c   Murillas, J ^d   Garcia Pardo, G ^e   Espejo, E ^a   Padilla, B ^f   Garcia Reyne, A ^g   Pasquau, J ^h   Rodriguez Bano J ⁱ   Lopez Contreras J ^j   Montero, M ^a   De La Calle, C ^a   Pintado, V ^k   Calbo, E ^l   Gasch, O ^m   Montejo, M ⁿ   Salavert, M ^o   Garcia Pais, M J ^p   Carratala J ^a   Pujol, M ^a   more..

^a HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^b HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^c HOSPITAL UNIVERSITARI ARNAU DE VILANOVA   (Spain)

^d HOSPITAL UNIVERSITARIO SON ESPASES   (Spain)

^e HOSPITAL UNIVERSITARI JOAN XXIII   (Spain)

^f HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^g HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^h HOSPITAL UNIVERSITARIO VIRGEN DE LAS NIEVES   (Spain)

ⁱ HOSPITAL UNIVERSITARIO VIRGEN MACARENA   (Spain)

^j HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^k HOSPITAL RAMÓN Y CAJAL   (Spain)

^l HOSPITAL MÚTUA DE TERRASSA   (Spain)

^m Servicio de Oncología Médica   (Spain)

ⁿ HOSPITAL DE CRUCES   (Spain)

^o HOSPITAL UNIVERSITARIO LA FE   (Spain)

^p HOSPITAL UNIVERSITARIO LUCUS AUGUSTI   (Spain)

more..

Author keywords

[No Author keywords available]

Indexed keywords

DAPTOMYCIN; FOSFOMYCIN; ANTIINFECTIVE AGENT; DRUG COMBINATION;

ADULT; ANTIBIOTIC THERAPY; ARTICLE; BLOOD CULTURE; CONTROLLED STUDY; DRUG MEGADOSE; DRUG MONITORING; DRUG RESPONSE; DRUG SAFETY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; HUMAN; MAJOR CLINICAL STUDY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MONOTHERAPY; MULTICENTER STUDY (TOPIC); OPEN STUDY; OUTCOME ASSESSMENT; PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); RECOMMENDED DRUG DOSE; STAPHYLOCOCCAL BACTEREMIA; STUDY DESIGN; TREATMENT DURATION; ADOLESCENT; BACTEREMIA; CLINICAL TRIAL; COMPARATIVE STUDY; DRUG COMBINATION; GROWTH, DEVELOPMENT AND AGING; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHODOLOGY; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MULTICENTER STUDY; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; STAPHYLOCOCCAL INFECTIONS; TREATMENT OUTCOME;

ADOLESCENT; ADULT; ANTI-BACTERIAL AGENTS; BACTEREMIA; DAPTOMYCIN; DRUG COMBINATIONS; FOSFOMYCIN; HUMANS; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIAL SENSITIVITY TESTS; RESEARCH DESIGN; STAPHYLOCOCCAL INFECTIONS; TREATMENT OUTCOME;

EID: 84926430017     PISSN: None     EISSN: 20446055     Source Type: Journal    
DOI: 10.1136/bmjopen-2014-006723     Document Type: Article

References (26)

1. Cosgrove SE, Sakoulas G, Perencevich EN, et al. Comparison of mortality associated with meticillin- resistant and meticillin-susceptible Staphylococcus aureus bacteremia: a meta-analysis. Clin Infect Dis 2003;36:53-9.
2. Gasch O, Ayats J, Dominguez MA, et al. Epidemiology of methicillin-resistant Staphylococcus aureus (MRSA) bloodstream infection: secular trends over 19 years at a university hospital. Medicine (Baltimore) 2011;90:319-27.
3. Gasch O, Camoez M, Dominguez MA, et al. Predictive factors for mortality in patients with methicillin-resistant Staphylococcus aureus bloodstream infection: impact on outcome of host, microorganism and therapy. Clin Microbiol Infect 2013;19:1049-57.
4. Chang FY, Peacock JE Jr, Musher DM, et al. Staphylococcus aureus bacteremia: recurrence and the impact of antibiotic treatment in a prospective multicenter study. Medicine 2003;82:333-9.
5. Schweizer ML, Furuno JP, Harris AD, et al. Comparative effectiveness of nafcillin or cefazolin versus vancomycin in methicillin-susceptible Staphylococcus aureus bacteremia. BMC Infect Dis 2011;11:279.
6. Fowler VG, Boucher HW, Corey GR, et al. Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. N Engl J Med 2006;355:653-65.
7. Wu G, Abraham T, Rapp J, et al. Daptomycin: evaluation of a high-dose treatment strategy. Int J Antimicrob Agents 2011;38:192-6.
8. Rehm SJ, Boucher H, Levine D, et al. Daptomycin versus vancomycin plus gentamicin for treatment of bacteraemia and endocarditis due to Staphylococcus aureus: subset analysis of patients infected with methicillin-resistant isolates. J Antimicrob Chemother 2008;62:1413-21.
9. Liu C, Bayer A, Cosgrove SE, et al. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin resistant Staphylococcus aureus infections in adults and children: executive summary. Clin Infect Dis 2011;52:285-92.
10. Gudiol F, Aguado JM, Pacual A, et al. Consensus document for the treatment of bacteremia and endocarditis caused by methicillin-resistant Staphylococcus aureus. Enferm Infecc Microbiol Clin 2009;27:105-15.
11. Kullar R, Davis SL, Levine DP, et al. High-dose daptomycin for treatment of complicated Gram-positive infections. Pharmacotherapy 2011;31:527-36.
12. Yang SJ, Xiong YQ, Boyle-Vavra S, et al. Daptomycin-oxacillin combinations in treatment of experimental endocarditis caused by daptomycin-nonsusceptible strains of methicillin-resistant Staphylococcus aureus with evolving oxacillin susceptibility (the "seesaw effect"). Antimicrob Agents Chemother 2010;54:3161-9.
13. Mehta S, Singh C, Plata KB, et al. β-Lactams increase the antibacterial activity of daptomycin against clinical methicillin-resistant Staphylococcus aureus strains and prevent selection of daptomycin-resistant derivatives. Antimicrob Agents Chemother 2012;56:6192-200.
14. LaPlante KL, Woodmansee S. Activities of daptomycin and vancomycin alone and in combination with rifampin and gentamicin against biofilm-forming methicillin-resistant Staphylococcus aureus isolates in an experimental model of endocarditis. Antimicrob Agents Chemother 2009;53:3880-6.
15. Miró JM, Garcia de la Maria C, Armero Y, et al. Addition of gentamicin or rifampin does not enhance the effectiveness of daptomycin in treatment of experimental endocarditis due to methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 2009;53:4172-7.
16. Dhand A, Bayer AS, Pogliano J, et al. Use of antistaphylococcal beta-lactams to increase daptomycin activity in eradicating persistent bacteremia due to methicillin-resistant Staphylococcus aureus: role of enhanced daptomycin binding. Clin Infect Dis 2011;53:158-63.
17. Popovic M, Steinort D, Pillai S, et al. Fosfomycin: an old, new friend? Eur J Clin Microbiol Infect Dis 2010;29:127-42.
18. Kastoris AC, Rafailidis PI, Vouloumanou EK, et al. Synergy of fosfomycin with other antibiotics for Gram-positive and Gram negative bacteria. Eur J Clin Pharmacol 2010;66:359-68.
19. Miró J, Entenza JM, del Rio A, et al. High-dose daptomycin plus fosfomycin was safe and effective in treating methicillin-susceptible and methicillin-resistant Staphylococcus aureus endocarditis: from bench to bedside. Antimicrob Agents Chemother 2012;56:4511-15.
20. Combination of daptomycin plus fosfomycin has synergistic, potent and rapid bactericidal activity against meticillin-resistant Staphylococcus aureus (MRSA) in a rabbit model of experimental endocarditis (EE). P0088. 24th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) Barcelona, Spain 10-13 May 2014.
21. Chen LY, Huang CH, Kuo SC, et al. High-dose daptomycin and fosfomycin treatment of a patient with endocarditis caused by daptomycin non susceptible Staphylococcus aureus: case report. BMC Infect Dis 2011;26:152.
22. Soriano A, Marco F, Martinez JA, et al. Influence of vancomycin mínimum inhibitory concentration on the treatment of methicillin-resistant Staphylococcus aureus bacteremia. Clin Infect Dis 2008;46:193-200.
23. van Hal SJ, Lodise TP, Paterson DL. The clinical significance of vancomycin minimum inhibitory concentration in Staphylococcus aureus infections: a systematic review and meta-analysis. Clin Infect Dis 2012;54:755-71.
24. Hawser SP, Bouchillon SK, Hoban DJ, et al. Rising incidence of Staphylococcus aureus with reduced susceptibility to vancomycin and susceptibility to antibiotics: a global analysis 2004-2009. Int J Antimicrob Agents 2011;37:219-24.
25. Daptomycin. Summary of product characteristics. http://www.ema.europa.eu/docs/en-GB/document-library/EPAR---Product-Information/human/000637/WC500036049.pdf [cited 24 Nov 2014].
26. Fosfomicina disódica. Agencia española de medicamentos y productos sanitarios. Ministerio de sanidad política social y Igualdad. 2003. http://www.aemps.gob.es/cima/pdfs/es/ft/54165/FT-54165.pdf [cited 24 Nov 2014].